Rasdegafusp alfa

N/A

Report date: 2025/11/10 20:01:49

Base Information

Drug NameRasdegafusp alfa
Drug Alias NameDEC205/NYESO1 vaccine CelldexCDX-1401
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionLymphocyte antigen 75 agonistsCancer/testis antigen 1 stimulants
TargetsLymphocyte antigen 75Cancer/testis antigen 1
Therapy Area/IndicationsUveal melanomaSkin MelanomaHormone-Resistant Prostate Neoplasms +[32] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLudwig Institute For Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCelldex TherapeuticsRoswell Park Cancer InstituteYale University +[4] 
Active IndicationsN/A
Inactive IndicationsUveal melanomaSkin MelanomaHormone-Resistant Prostate Neoplasms +[32] 

Other Information

ATC CodeN/A
Related LinksN/A